Abemaciclib: beside a new treatment under test
57 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 1. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerNot yet recruitingNCT07935317Phase 2Report a problem
- A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast CancerRecruitingNCT07905001Phase 1Report a problem
- A Study to Evaluate ATX-898 in Participants With Advanced Solid TumorsRecruitingNCT07767474Phase 1/2Report a problem
- Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.Not yet recruitingNCT07717450Phase 3Report a problem
- Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerRecruitingNCT07180160Phase 2Report a problem
- A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast CancerNot yet recruitingNCT07173556Phase 1/2Report a problem
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 1Report a problem
- A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast CancerRecruitingNCT07112053Phase 2Report a problem
- Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast CancerRecruitingNCT07037199Phase 2Report a problem
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingNCT07002177Phase 1/2Report a problem
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossRecruitingNCT06810544Phase 1/2Report a problem
- Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNot yet recruitingNCT06561022Phase 2Report a problem
- NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast CancerRecruitingNCT06259929Phase 2Report a problem
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingNCT05891093Phase 3Report a problem
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingNCT05867251Phase 1/2Report a problem
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCRecruitingNCT05774899Phase 1/2Report a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2Report a problem
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerRecruitingNCT05735080Phase 1/2Report a problem
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationRecruitingNCT05696626Phase 3Report a problem
- VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingNCT05608252Phase 1/2Report a problem
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingNCT05573126Phase 1/2Report a problem
- Chidamide in Combination With Abemaciclib and Endocrinotherapy(Doctor's Choice) in Breast Cancer Patients Previously Treated With PalbociclibRecruitingNCT05464173Phase 1/2Report a problem
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingNCT05386108Phase 1/2Report a problem
- Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsRecruitingNCT05372640Phase 1Report a problem
- A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of AdultsEnrolling by invitationNCT05189717Phase 1Report a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2Report a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2Report a problem
- Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesRecruitingNCT04092673Phase 1/2Report a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2Report a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2Report a problem
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Phase 3Results postedReport a problem
- A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.TerminatedNCT04534283Phase 2Results postedReport a problem
- A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C MutationTerminatedNCT04165031Phase 1/2Results postedReport a problem
- Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerTerminatedNCT03284957Phase 1/2Results postedReport a problem
- This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast CancerCompletedNCT03099174Phase 1Results postedReport a problem
- A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT02784795Phase 1Results postedReport a problem
- ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerCompletedNCT06570031Phase 1Report a problem
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingNCT06188520Phase 1/2Report a problem
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingNCT05952557Phase 3Report a problem
- First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsCompletedNCT05759949Phase 1Report a problem
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruitingNCT05708235Phase 2Report a problem
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingNCT05563220Phase 1/2Report a problem
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Active, not recruitingNCT05548127Phase 1/2Report a problem
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingNCT05307705Phase 1Report a problem
- Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerTerminatedNCT05065411Phase 3Report a problem
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2Report a problem
- Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3Report a problem
- Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerTerminatedNCT04791384Phase 1/2Report a problem
- LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04616183Phase 1/2Report a problem
- A Study of ZN-c5 and Abemaciclib in Participants With Breast CancerCompletedNCT04514159Phase 1Report a problem
- Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationCompletedNCT04432454Phase 2Report a problem
- LY3214996 Plus Abemaciclib in Recurrent Glioblastoma PatientsCompletedNCT04391595Early Phase 1Report a problem
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingNCT04188548Phase 1Report a problem
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1Report a problem
- A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerCompletedNCT02857270Phase 1Report a problem
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsCompletedNCT02791334Phase 1Report a problem
- A Study of LY3023414 in Participants With Advanced CancerCompletedNCT01655225Phase 1Report a problem